Ikaria gets FDA OK for new software on infant drug delivery device

11/14/2012 | MassDevice.com (Boston)

The FDA has given Ikaria 510(k) clearance to update software on its Inomax DSIR device designed to deliver the firm's Inomax vasodilator agent, an FDA-approved treatment for infant hypoxic respiratory failure tied to pulmonary hypertension. The firm also gained FDA clearance for three devices used with the Inomax DSIR for noninvasive respiratory care.

View Full Article in:

MassDevice.com (Boston)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY